Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins
•Assessing sphingolipid distribution in plasma lipoproteins is clinically valuable.•Plasma levels do not consistently reflect changes in circulating lipoproteins.•HDL sphingolipids are significantly lower in diabetes than in controls.•LDL sphingomyelins are higher in patients with diabetes and macro...
Saved in:
Published in | Journal of clinical lipidology Vol. 16; no. 2; pp. 173 - 183 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Assessing sphingolipid distribution in plasma lipoproteins is clinically valuable.•Plasma levels do not consistently reflect changes in circulating lipoproteins.•HDL sphingolipids are significantly lower in diabetes than in controls.•LDL sphingomyelins are higher in patients with diabetes and macroalbuminuria.
We have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our studies into type 2 diabetes.
This study proposes comparing the levels of plasma sphingolipids and their distribution in circulating lipoproteins (VLDL/IDL, LDL, HDL2 and HDL3) between a healthy control group and two groups of subjects with type 2 diabetes, one with and other without MA.
Plasma and lipoprotein sphingolipids/glycosphingolipids were measured using HPLC-MS/MS in 114 subjects (40 controls; 74 type 2 diabetes, 40 without MA; and 34 with MA) and the levels were compared between controls and the two groups of diabetes. Group effect sizes were calculated using Cohen's d.
Sphingomyelin species carried by LDL are significantly higher in diabetic patients with MA than in those with normal albumin excretion rate (AER). Compared to controls, significant decreases in the levels of sphingolipids carried by HDL in patients with diabetes with normal AER or MA were observed for all sphingolipid classes except for hexosylceramide, which was normal in diabetic patients without MA. Although lower than in controls, the levels of lactosylceramides carried by HDL2/HDL3 were significantly higher in diabetes with MA.
Considering the critical role sphingolipids play in major cell biological responses and cell signaling pathways, the consequences for disease development of changes in the distribution of sphingolipids/glycosphingolipids carried by lipoproteins could be considerable. Our work is just a first step to address a considerable gap in our present knowledge in this important field. |
---|---|
AbstractList | We have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our studies into type 2 diabetes.
This study proposes comparing the levels of plasma sphingolipids and their distribution in circulating lipoproteins (VLDL/IDL, LDL, HDL2 and HDL3) between a healthy control group and two groups of subjects with type 2 diabetes, one with and other without MA.
Plasma and lipoprotein sphingolipids/glycosphingolipids were measured using HPLC-MS/MS in 114 subjects (40 controls; 74 type 2 diabetes, 40 without MA; and 34 with MA) and the levels were compared between controls and the two groups of diabetes. Group effect sizes were calculated using Cohen's d.
Sphingomyelin species carried by LDL are significantly higher in diabetic patients with MA than in those with normal albumin excretion rate (AER). Compared to controls, significant decreases in the levels of sphingolipids carried by HDL in patients with diabetes with normal AER or MA were observed for all sphingolipid classes except for hexosylceramide, which was normal in diabetic patients without MA. Although lower than in controls, the levels of lactosylceramides carried by HDL2/HDL3 were significantly higher in diabetes with MA.
Considering the critical role sphingolipids play in major cell biological responses and cell signaling pathways, the consequences for disease development of changes in the distribution of sphingolipids/glycosphingolipids carried by lipoproteins could be considerable. Our work is just a first step to address a considerable gap in our present knowledge in this important field. •Assessing sphingolipid distribution in plasma lipoproteins is clinically valuable.•Plasma levels do not consistently reflect changes in circulating lipoproteins.•HDL sphingolipids are significantly lower in diabetes than in controls.•LDL sphingomyelins are higher in patients with diabetes and macroalbuminuria. We have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our studies into type 2 diabetes. This study proposes comparing the levels of plasma sphingolipids and their distribution in circulating lipoproteins (VLDL/IDL, LDL, HDL2 and HDL3) between a healthy control group and two groups of subjects with type 2 diabetes, one with and other without MA. Plasma and lipoprotein sphingolipids/glycosphingolipids were measured using HPLC-MS/MS in 114 subjects (40 controls; 74 type 2 diabetes, 40 without MA; and 34 with MA) and the levels were compared between controls and the two groups of diabetes. Group effect sizes were calculated using Cohen's d. Sphingomyelin species carried by LDL are significantly higher in diabetic patients with MA than in those with normal albumin excretion rate (AER). Compared to controls, significant decreases in the levels of sphingolipids carried by HDL in patients with diabetes with normal AER or MA were observed for all sphingolipid classes except for hexosylceramide, which was normal in diabetic patients without MA. Although lower than in controls, the levels of lactosylceramides carried by HDL2/HDL3 were significantly higher in diabetes with MA. Considering the critical role sphingolipids play in major cell biological responses and cell signaling pathways, the consequences for disease development of changes in the distribution of sphingolipids/glycosphingolipids carried by lipoproteins could be considerable. Our work is just a first step to address a considerable gap in our present knowledge in this important field. We have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our studies into type 2 diabetes.BACKGROUNDWe have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our studies into type 2 diabetes.This study proposes comparing the levels of plasma sphingolipids and their distribution in circulating lipoproteins (VLDL/IDL, LDL, HDL2 and HDL3) between a healthy control group and two groups of subjects with type 2 diabetes, one with and other without MA.OBJECTIVEThis study proposes comparing the levels of plasma sphingolipids and their distribution in circulating lipoproteins (VLDL/IDL, LDL, HDL2 and HDL3) between a healthy control group and two groups of subjects with type 2 diabetes, one with and other without MA.Plasma and lipoprotein sphingolipids/glycosphingolipids were measured using HPLC-MS/MS in 114 subjects (40 controls; 74 type 2 diabetes, 40 without MA; and 34 with MA) and the levels were compared between controls and the two groups of diabetes. Group effect sizes were calculated using Cohen's d.METHODSPlasma and lipoprotein sphingolipids/glycosphingolipids were measured using HPLC-MS/MS in 114 subjects (40 controls; 74 type 2 diabetes, 40 without MA; and 34 with MA) and the levels were compared between controls and the two groups of diabetes. Group effect sizes were calculated using Cohen's d.Sphingomyelin species carried by LDL are significantly higher in diabetic patients with MA than in those with normal albumin excretion rate (AER). Compared to controls, significant decreases in the levels of sphingolipids carried by HDL in patients with diabetes with normal AER or MA were observed for all sphingolipid classes except for hexosylceramide, which was normal in diabetic patients without MA. Although lower than in controls, the levels of lactosylceramides carried by HDL2/HDL3 were significantly higher in diabetes with MA.RESULTSSphingomyelin species carried by LDL are significantly higher in diabetic patients with MA than in those with normal albumin excretion rate (AER). Compared to controls, significant decreases in the levels of sphingolipids carried by HDL in patients with diabetes with normal AER or MA were observed for all sphingolipid classes except for hexosylceramide, which was normal in diabetic patients without MA. Although lower than in controls, the levels of lactosylceramides carried by HDL2/HDL3 were significantly higher in diabetes with MA.Considering the critical role sphingolipids play in major cell biological responses and cell signaling pathways, the consequences for disease development of changes in the distribution of sphingolipids/glycosphingolipids carried by lipoproteins could be considerable. Our work is just a first step to address a considerable gap in our present knowledge in this important field.CONCLUSIONSConsidering the critical role sphingolipids play in major cell biological responses and cell signaling pathways, the consequences for disease development of changes in the distribution of sphingolipids/glycosphingolipids carried by lipoproteins could be considerable. Our work is just a first step to address a considerable gap in our present knowledge in this important field. |
Author | Hunt, Kelly J Lopes-Virella, Maria F Hammad, Samar M Baker, Nathaniel L Klein, Richard L |
Author_xml | – sequence: 1 givenname: Samar M surname: Hammad fullname: Hammad, Samar M email: hammadsm@musc.edu organization: Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA – sequence: 2 givenname: Kelly J surname: Hunt fullname: Hunt, Kelly J organization: Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA – sequence: 3 givenname: Nathaniel L surname: Baker fullname: Baker, Nathaniel L organization: Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA – sequence: 4 givenname: Richard L surname: Klein fullname: Klein, Richard L organization: Division of Diabetes, Endocrinology and Medical Genetics, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA – sequence: 5 givenname: Maria F orcidid: 0000-0001-5572-1700 surname: Lopes-Virella fullname: Lopes-Virella, Maria F email: virellam@musc.edu organization: Division of Diabetes, Endocrinology and Medical Genetics, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35148982$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkTtvVDEQhS0URB7wByiQS5q72L5PIxoUSECKRAO15TseE-967cX2Rbr_Hq82aVKEakaa881ozrkkZyEGJOQtZxvO-PBhu9lq8BvBBN9wsWGse0Eu-DQOTTdO8qz2sm0bMY3dObnMectY34-sf0XO2553k5zEBYlfnJ6xYKY6GLpzJuBKzZrtEqC4GOhepx0av1LtCyZa7pFCDAVDodHSfLh34Xf07uBMpqBTcmjovFJwCRavS53SOo2HFAu6kF-Tl1b7jG8e6hX5dfP15_W35u7H7ffrz3cNdD0vzWxmkDOzeuhQ8AFGxvncasm1xHmYTQsMhtFyA7KVwo7Cyt4OZrA9A5Dd1F6R96e99fCfBXNRe5cBvdcB45KVGMQk5NRzVqXvHqTLvEejDsnVp1f1aFIVTCcBpJhzQqvAFX10pyTtvOJMHfNQW3XMQx3zUFyomkdFxRP0cfuz0KcThNWgvw6TyuAwABqXEIoy0T2Pf3yCg3fBgfY7XP8H_wMpHroQ |
CitedBy_id | crossref_primary_10_1080_07435800_2025_2479256 crossref_primary_10_1007_s00424_024_03029_5 crossref_primary_10_3390_jcm13175050 crossref_primary_10_3390_ijms241814015 crossref_primary_10_1016_j_jacl_2024_07_004 crossref_primary_10_3389_fphys_2023_1229108 crossref_primary_10_3390_biomedicines12010190 crossref_primary_10_1080_17460441_2023_2292039 |
Cites_doi | 10.2337/db08-1228 10.1681/ASN.V72171 10.1194/jlr.P119000543 10.1016/j.metabol.2014.07.001 10.1007/978-3-030-21162-2_7 10.1038/s41598-019-52916-w 10.1161/ATVBAHA.115.307049 10.1007/978-1-4419-6741-1_14 10.1194/jlr.M087502 10.3390/genes11020178 10.1371/journal.pone.0224496 10.1016/j.tem.2017.03.005 10.1021/pr201036j 10.1038/sj.ki.5001834 10.1172/jci.insight.130317 10.1146/annurev-physiol-031620-093815 10.1016/j.aca.2011.01.034 10.1074/jbc.M115.659110 10.1016/j.jacl.2019.02.004 10.2337/diab.32.1.20 10.1194/jlr.D008532 10.1194/jlr.M003988 10.1371/journal.pone.0192616 10.1016/j.ekir.2016.12.003 10.1007/s00125-020-05201-9 10.1042/bj3520809 10.1007/s00395-008-0769-1 10.1007/BF01469685 10.1016/j.jdiacomp.2020.107734 10.1016/j.atherosclerosis.2015.06.040 10.1155/2012/180705 10.1007/s11306-011-0343-y 10.1007/978-3-7091-1511-4_19 10.1016/j.talanta.2011.05.036 10.1186/1475-2840-12-27 10.1016/j.jacl.2019.03.005 10.1016/j.chemphyslip.2008.06.003 10.3389/fendo.2020.622692 |
ContentType | Journal Article |
Copyright | 2022 Copyright © 2022. Published by Elsevier Inc. |
Copyright_xml | – notice: 2022 – notice: Copyright © 2022. Published by Elsevier Inc. |
DBID | AAYXX CITATION NPM 7X8 |
DOI | 10.1016/j.jacl.2021.12.004 |
DatabaseName | CrossRef PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1876-4789 |
EndPage | 183 |
ExternalDocumentID | 35148982 10_1016_j_jacl_2021_12_004 S1933287421003512 |
Genre | Journal Article |
GroupedDBID | --- --K --M -RU .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXUO AAYWO ABBQC ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OA. OAUVE OL~ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SDF SDG SEL SES SPCBC SSH SSZ T5K Z5R ~G- AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AJBFU AJOXV AMFUW EFLBG LCYCR RIG AAYXX AGRNS CITATION NPM 7X8 |
ID | FETCH-LOGICAL-c451t-bdbc9b0fa64e216c7011b3a91a9eb6bd3c0c67f1dc9392f72f95f6d6f50cc9483 |
IEDL.DBID | .~1 |
ISSN | 1933-2874 |
IngestDate | Tue Aug 05 10:00:41 EDT 2025 Mon Jul 21 05:58:02 EDT 2025 Tue Jul 01 03:29:24 EDT 2025 Thu Apr 24 23:05:30 EDT 2025 Fri Feb 23 02:39:36 EST 2024 Tue Aug 26 16:38:26 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Type 2 diabetes eGFR ESRD Lactosylceramide Sphingolipid Albuminuria AER Cer S1P Dihydrosphingosine Hex-Cer MA Glycosphingolipid dhsph Hexosylceramide Sphingosine Sphingomyelin Ceramide Lac-Cer SM dhsph-1 Macroalbuminuria |
Language | English |
License | Copyright © 2022. Published by Elsevier Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c451t-bdbc9b0fa64e216c7011b3a91a9eb6bd3c0c67f1dc9392f72f95f6d6f50cc9483 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0001-5572-1700 |
OpenAccessLink | http://www.lipidjournal.com/article/S1933287421003512/pdf |
PMID | 35148982 |
PQID | 2628298510 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2628298510 pubmed_primary_35148982 crossref_citationtrail_10_1016_j_jacl_2021_12_004 crossref_primary_10_1016_j_jacl_2021_12_004 elsevier_sciencedirect_doi_10_1016_j_jacl_2021_12_004 elsevier_clinicalkey_doi_10_1016_j_jacl_2021_12_004 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | March-April 2022 2022-03-00 2022 Mar-Apr 20220301 |
PublicationDateYYYYMMDD | 2022-03-01 |
PublicationDate_xml | – month: 03 year: 2022 text: March-April 2022 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of clinical lipidology |
PublicationTitleAlternate | J Clin Lipidol |
PublicationYear | 2022 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Lopes-VIrella, Wohltmann, Mayfield, Loadholt, Colwell (bib0025) 1983; 32 Hammad, Al Gadban, Semler, Klein (bib0026) 2012 Zakiev, Rached, Lhomme, Darabi-Amin, Ponnaiah, Becker, Therond p, Serrano, Santos, Chapman, Orekhov, Kontush (bib0028) 2019; 13 (bib0015) 2014 Haus, Kashyap, Kasumov, Zhang, Kelly, Defronzo, Kirwan (bib0008) 2009; 58 Lee, Hammad, Semler, Luttrell, Lopes-Virella, Klein (bib0024) 2010; 51 Tong, Peng, Liu, Ji, Niu, Ren, Pan, Hu, Zheng, Huang (bib0035) 2013; 12 Denimal, Pais de Barros, Petit, Bouillet, Vergès, Duvillard (bib0038) 2015; 241 Han, Xia, Liang, Wang, Wang, Hu, Li, Luo (bib0020) 2011; 689 Chaurasia, Summers (bib0032) 2021; 83 Klein, Hammad, Baker, Hunt, Al Gadban, Cleary, Virella, Lopes-Virella (bib0003) 2014; 63 Kremer, Atzpodien, Schnellbacher (bib0007) 1975; 53 Hammad, Twal, Arif, Semler, Klein, Nihalani (bib0039) 2020; 11 Kumpula, Kumpula, Taskinen, Jauhiainen, Kaski, Ala-Korpela (bib0011) 2008; 155 Hammad, Hardin, Wilson, Twal, Nietert, Oates (bib0027) 2019; 14 Iqbal, Walsh, Hammad, Cuchel, Rader, Hussain (bib0014) 2018; 59 Russo, Ross, Cowart (bib0006) 2013 Mäkinen, Tynkkynen, Soininen, Forsblom, Peltola, Kangas, Groop, Ala-Korpela (bib0017) 2012; 8 Mäkinen, Tynkkynen, Soininen, Peltola, Kanga, Forsblom, Thorn, Kaski, Laatikainen, Ala-Korpela, Groop (bib0016) 2012; 11 Nicholson, Pezzolesi, Summers (bib0033) 2021; 11 Fox, Kester (bib0001) 2010; 688 Afshinnia, Nair, Lin, Rajendiran, Soni, Byun, Sharma, Fort, Gardner, Looker, Nelson, Brosius, Feldman, Michailidis, Kretzler, Pennathur (bib0023) 2019; 4 Shayman (bib0030) 1996; 7 Weinberg (bib0031) 2006; 70 Brinck, Thomas, Lauer, Jornayvaz, Brulhart-Meynet, Prost, Pataky, Löfgren, Hoffstedt, Eriksson, Pramfalk, Morel, Kwak, van Eck, James, Frias (bib0036) 2016; 36 Pongrac Barlovic, Harjutsalo, Sandholm, Forsblom (bib0018) 2020; 63 Lopes-Virella, Baker, Hunt, Hammad, Arthur, Virella, Klein, Group (bib0004) 2019; 13 Tofte, Suvitaival, Ahonen, Winther, Theilade, Frimodt-Møller, Ahluwalia, Rossing (bib0019) 2019; 9 Randriamboavonjy, Badenhoop, Schmidt, Geisslinger, Fisslthaler, Fleming (bib0034) 2009; 104 Hammad, Pierce, Soodavar, Smith, Al Gadban, Rembiesa, Klein, Hannun, Bielawski, Bielawska (bib0010) 2010; 51 Liu, Ghosh, Kovalik, Ching, Choi, Tavintharan, Ong, Sum, Summers, Tai, Lim (bib0022) 2016; 2 Matanes, Twal, Hammad (bib0009) 2019; 1159 Iqbal, Walsh, Hammad, Cuchel, Tarugi, Hegele, Davidson, Rader, Klein, Hussain (bib0013) 2015; 290 Murata, Sato, Kon, Tomura, Yanagita, Kuwabara, Ui, Okajima (bib0012) 2000; 352 Iqbal, Walsh, Hammad (bib0005) 2017; 28 Zhu, Liang, Hu, Wang, Luo (bib0021) 2011; 85 Chapman, Orsoni, Tan, Mellett, Nguyen, Robillard, Giral, Therond, Meikle (bib0029) 2020; 61 Mandal, Grambergs, Mondal, Basu, Tahia, Dagogo-Jack (bib0002) 2021; 35 Vaisar, Couzens, Hwang, Russell, Barlow, DeFina, Hoofnagle, Kim (bib0037) 2018; 13 Chaurasia (10.1016/j.jacl.2021.12.004_bib0032) 2021; 83 Klein (10.1016/j.jacl.2021.12.004_bib0003) 2014; 63 Lopes-Virella (10.1016/j.jacl.2021.12.004_bib0004) 2019; 13 Haus (10.1016/j.jacl.2021.12.004_bib0008) 2009; 58 Fox (10.1016/j.jacl.2021.12.004_bib0001) 2010; 688 (10.1016/j.jacl.2021.12.004_bib0015) 2014 Matanes (10.1016/j.jacl.2021.12.004_bib0009) 2019; 1159 Iqbal (10.1016/j.jacl.2021.12.004_bib0013) 2015; 290 Afshinnia (10.1016/j.jacl.2021.12.004_bib0023) 2019; 4 Denimal (10.1016/j.jacl.2021.12.004_bib0038) 2015; 241 Iqbal (10.1016/j.jacl.2021.12.004_bib0014) 2018; 59 Chapman (10.1016/j.jacl.2021.12.004_bib0029) 2020; 61 Mandal (10.1016/j.jacl.2021.12.004_bib0002) 2021; 35 Hammad (10.1016/j.jacl.2021.12.004_bib0039) 2020; 11 Hammad (10.1016/j.jacl.2021.12.004_bib0026) 2012 Brinck (10.1016/j.jacl.2021.12.004_bib0036) 2016; 36 Lee (10.1016/j.jacl.2021.12.004_bib0024) 2010; 51 Weinberg (10.1016/j.jacl.2021.12.004_bib0031) 2006; 70 Lopes-VIrella (10.1016/j.jacl.2021.12.004_bib0025) 1983; 32 Tofte (10.1016/j.jacl.2021.12.004_bib0019) 2019; 9 Zhu (10.1016/j.jacl.2021.12.004_bib0021) 2011; 85 Vaisar (10.1016/j.jacl.2021.12.004_bib0037) 2018; 13 Mäkinen (10.1016/j.jacl.2021.12.004_bib0017) 2012; 8 Han (10.1016/j.jacl.2021.12.004_bib0020) 2011; 689 Murata (10.1016/j.jacl.2021.12.004_bib0012) 2000; 352 Zakiev (10.1016/j.jacl.2021.12.004_bib0028) 2019; 13 Kumpula (10.1016/j.jacl.2021.12.004_bib0011) 2008; 155 Kremer (10.1016/j.jacl.2021.12.004_bib0007) 1975; 53 Iqbal (10.1016/j.jacl.2021.12.004_bib0005) 2017; 28 Hammad (10.1016/j.jacl.2021.12.004_bib0010) 2010; 51 Mäkinen (10.1016/j.jacl.2021.12.004_bib0016) 2012; 11 Russo (10.1016/j.jacl.2021.12.004_bib0006) 2013 Nicholson (10.1016/j.jacl.2021.12.004_bib0033) 2021; 11 Tong (10.1016/j.jacl.2021.12.004_bib0035) 2013; 12 Pongrac Barlovic (10.1016/j.jacl.2021.12.004_bib0018) 2020; 63 Liu (10.1016/j.jacl.2021.12.004_bib0022) 2016; 2 Hammad (10.1016/j.jacl.2021.12.004_bib0027) 2019; 14 Shayman (10.1016/j.jacl.2021.12.004_bib0030) 1996; 7 Randriamboavonjy (10.1016/j.jacl.2021.12.004_bib0034) 2009; 104 |
References_xml | – volume: 14 year: 2019 ident: bib0027 article-title: Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity publication-title: PLoS One – volume: 51 start-page: 2619 year: 2010 end-page: 2628 ident: bib0024 article-title: HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate publication-title: J Lipid Res – volume: 7 start-page: 171 year: 1996 end-page: 182 ident: bib0030 article-title: Sphingolipids: their role in intracellular signaling and renal growth publication-title: J Am Soc Nephrol – volume: 83 start-page: 303 year: 2021 end-page: 330 ident: bib0032 article-title: Ceramides in metabolism: key lipotoxic players publication-title: Annu Rev Physiol – volume: 352 start-page: 809 year: 2000 end-page: 815 ident: bib0012 article-title: Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions publication-title: Biochem J – volume: 13 year: 2018 ident: bib0037 article-title: Type 2 diabetes is associated with loss of HDL endothelium protective functions publication-title: PLoS One – year: 2014 ident: bib0015 article-title: 2014 USRDS annual data report: epidemiology of kidney disease in the United States – volume: 61 start-page: 911 year: 2020 end-page: 932 ident: bib0029 article-title: LDL subclass lipidomics in atherogenic dyslipidemia:effect of statin therapy on bioactive lipids and dense LDL publication-title: J. Lipid Res – volume: 4 year: 2019 ident: bib0023 article-title: Increased lipogenesis and impaired beta-oxidation predict type 2 diabetic kidney disease progression in American Indians publication-title: JCI Insight – volume: 32 start-page: 20 year: 1983 end-page: 25 ident: bib0025 article-title: Effect of Metabolic Control on lipid, lipoprotein, and apolipoprotein levesl in 55 insulin-dependent diabetic patients. A longitudinal study publication-title: Diabetes – volume: 35 year: 2021 ident: bib0002 article-title: Role of ceramides in the pathogenesis of diabetes mellitus and its complications publication-title: J Diabetes Complications – volume: 2 start-page: 470 year: 2016 end-page: 480 ident: bib0022 article-title: Profiling of plasma metabolites suggests altered mitochondrial fuel usage and remodeling of sphingolipid metabolism in individuals with type 2 diabetes and kidney disease publication-title: Kidney Int Rep – volume: 63 start-page: 1287 year: 2014 end-page: 1295 ident: bib0003 article-title: Decreased plasma levels of select very long chain ceramides species are associated with the development of nephropathy in type 1 diabetes publication-title: Metabolism – volume: 12 start-page: 27 year: 2013 ident: bib0035 article-title: High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate publication-title: Cardiovasc Diabetol – volume: 13 start-page: 481 year: 2019 end-page: 491 ident: bib0004 article-title: Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes publication-title: J Clin Lipidol – volume: 11 start-page: 1782 year: 2012 end-page: 1790 ident: bib0016 article-title: Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study) publication-title: J Proteome Res – volume: 241 start-page: 752 year: 2015 end-page: 760 ident: bib0038 article-title: Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration publication-title: Atherosclerosis – volume: 688 start-page: 206 year: 2010 end-page: 216 ident: bib0001 article-title: Therapeutic strategies for diabetes and complications: a role for sphingolipids? publication-title: Adv Exp Med Biol – volume: 36 start-page: 817 year: 2016 end-page: 824 ident: bib0036 article-title: Diabetes mellitus is associated with reduced high-density lipoprotein sphingosine-1-phosphate content and impaired high-density lipoprotein cardiac cell protection publication-title: Arterioscler Thromb Vasc Biol – volume: 51 start-page: 3074 year: 2010 end-page: 3087 ident: bib0010 article-title: Blood sphingolipidomics in healthy humans: impact of sample collection and methodology publication-title: J Lipid Res – volume: 8 start-page: 369 year: 2012 end-page: 375 ident: bib0017 article-title: Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study) publication-title: Metabolomics – start-page: 373 year: 2013 end-page: 401 ident: bib0006 article-title: Sphingolipids in obesity, type 2 diabetes, and metabolic disease publication-title: Handb Exp Pharmacol – volume: 1159 start-page: 109 year: 2019 end-page: 138 ident: bib0009 article-title: Sphingolipids as Biomarkers of Disease publication-title: Adv Exp Med Biol – volume: 70 start-page: 1560 year: 2006 end-page: 1566 ident: bib0031 article-title: Lipotoxicity publication-title: Kidney Int – volume: 9 start-page: 16398 year: 2019 ident: bib0019 article-title: Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes publication-title: Sci Rep – volume: 85 start-page: 1711 year: 2011 end-page: 1720 ident: bib0021 article-title: Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy publication-title: Talanta – volume: 63 start-page: 1847 year: 2020 end-page: 1856 ident: bib0018 article-title: Groop PH; FinnDiane Study Group. Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes publication-title: Diabetologia – volume: 28 start-page: 506 year: 2017 end-page: 518 ident: bib0005 article-title: Hussain MM. Sphingolipids and Lipoproteins in Health and Metabolic Disorders publication-title: Trends Endocrinol Metab – volume: 155 start-page: 57 year: 2008 end-page: 62 ident: bib0011 article-title: Reconsideration of hydrophobic lipid distributions in lipoprotein particles publication-title: Chem. Phys. Lipids. – volume: 11 start-page: 178 year: 2020 ident: bib0039 article-title: Transcriptomics reveal altered metabolic and signaling pathways in podocytes exposed to C16 ceramide-enriched lipoproteins publication-title: Genes (Basel) – volume: 13 start-page: 468 year: 2019 end-page: 480 ident: bib0028 publication-title: .Journal of Clinical Lipidology – year: 2012 ident: bib0026 article-title: Sphingosine 1-phosphate distribution in plasma: associations with atypical lipoprotein profiles publication-title: J Lipids – volume: 53 start-page: 637 year: 1975 end-page: 638 ident: bib0007 article-title: Plasma glycosphingolipids in diabetics and normals publication-title: Klin Wochenschr – volume: 689 start-page: 85 year: 2011 end-page: 91 ident: bib0020 article-title: Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy publication-title: Anal Chim Acta – volume: 290 start-page: 25863 year: 2015 end-page: 25875 ident: bib0013 article-title: Microsomal triglyceride transfer protein transfers and determines plasma concentrations of ceramide and sphingomyelin but Not glycosylceramide publication-title: J Biol Chem – volume: 59 start-page: 2084 year: 2018 end-page: 2097 ident: bib0014 article-title: ATP binding cassette family A protein 1 determines hexosylceramide and sphingomyelin levels in human and mouse plasma publication-title: J Lipid Res – volume: 104 start-page: 333 year: 2009 end-page: 340 ident: bib0034 article-title: The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes publication-title: Basic Res Cardiol – volume: 58 start-page: 337 year: 2009 end-page: 343 ident: bib0008 article-title: Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance publication-title: Diabetes – volume: 11 year: 2021 ident: bib0033 article-title: Rotten to the cortex: ceramide-mediated lipotoxicity in diabetic kidney disease publication-title: Front Endocrinol (Lausanne) – volume: 58 start-page: 337 issue: 2 year: 2009 ident: 10.1016/j.jacl.2021.12.004_bib0008 article-title: Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance publication-title: Diabetes doi: 10.2337/db08-1228 – volume: 7 start-page: 171 issue: 2 year: 1996 ident: 10.1016/j.jacl.2021.12.004_bib0030 article-title: Sphingolipids: their role in intracellular signaling and renal growth publication-title: J Am Soc Nephrol doi: 10.1681/ASN.V72171 – volume: 61 start-page: 911 year: 2020 ident: 10.1016/j.jacl.2021.12.004_bib0029 article-title: LDL subclass lipidomics in atherogenic dyslipidemia:effect of statin therapy on bioactive lipids and dense LDL publication-title: J. Lipid Res doi: 10.1194/jlr.P119000543 – volume: 63 start-page: 1287 year: 2014 ident: 10.1016/j.jacl.2021.12.004_bib0003 article-title: Decreased plasma levels of select very long chain ceramides species are associated with the development of nephropathy in type 1 diabetes publication-title: Metabolism doi: 10.1016/j.metabol.2014.07.001 – volume: 1159 start-page: 109 year: 2019 ident: 10.1016/j.jacl.2021.12.004_bib0009 article-title: Sphingolipids as Biomarkers of Disease publication-title: Adv Exp Med Biol doi: 10.1007/978-3-030-21162-2_7 – volume: 9 start-page: 16398 issue: 1 year: 2019 ident: 10.1016/j.jacl.2021.12.004_bib0019 article-title: Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes publication-title: Sci Rep doi: 10.1038/s41598-019-52916-w – volume: 36 start-page: 817 issue: 5 year: 2016 ident: 10.1016/j.jacl.2021.12.004_bib0036 article-title: Diabetes mellitus is associated with reduced high-density lipoprotein sphingosine-1-phosphate content and impaired high-density lipoprotein cardiac cell protection publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.115.307049 – volume: 688 start-page: 206 year: 2010 ident: 10.1016/j.jacl.2021.12.004_bib0001 article-title: Therapeutic strategies for diabetes and complications: a role for sphingolipids? publication-title: Adv Exp Med Biol doi: 10.1007/978-1-4419-6741-1_14 – volume: 59 start-page: 2084 year: 2018 ident: 10.1016/j.jacl.2021.12.004_bib0014 article-title: ATP binding cassette family A protein 1 determines hexosylceramide and sphingomyelin levels in human and mouse plasma publication-title: J Lipid Res doi: 10.1194/jlr.M087502 – volume: 11 start-page: 178 issue: 2 year: 2020 ident: 10.1016/j.jacl.2021.12.004_bib0039 article-title: Transcriptomics reveal altered metabolic and signaling pathways in podocytes exposed to C16 ceramide-enriched lipoproteins publication-title: Genes (Basel) doi: 10.3390/genes11020178 – volume: 14 year: 2019 ident: 10.1016/j.jacl.2021.12.004_bib0027 article-title: Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity publication-title: PLoS One doi: 10.1371/journal.pone.0224496 – volume: 28 start-page: 506 year: 2017 ident: 10.1016/j.jacl.2021.12.004_bib0005 article-title: Hussain MM. Sphingolipids and Lipoproteins in Health and Metabolic Disorders publication-title: Trends Endocrinol Metab doi: 10.1016/j.tem.2017.03.005 – volume: 11 start-page: 1782 issue: 3 year: 2012 ident: 10.1016/j.jacl.2021.12.004_bib0016 article-title: Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study) publication-title: J Proteome Res doi: 10.1021/pr201036j – volume: 70 start-page: 1560 issue: 9 year: 2006 ident: 10.1016/j.jacl.2021.12.004_bib0031 article-title: Lipotoxicity publication-title: Kidney Int doi: 10.1038/sj.ki.5001834 – volume: 4 issue: 21 year: 2019 ident: 10.1016/j.jacl.2021.12.004_bib0023 article-title: Increased lipogenesis and impaired beta-oxidation predict type 2 diabetic kidney disease progression in American Indians publication-title: JCI Insight doi: 10.1172/jci.insight.130317 – volume: 83 start-page: 303 year: 2021 ident: 10.1016/j.jacl.2021.12.004_bib0032 article-title: Ceramides in metabolism: key lipotoxic players publication-title: Annu Rev Physiol doi: 10.1146/annurev-physiol-031620-093815 – volume: 689 start-page: 85 issue: 1 year: 2011 ident: 10.1016/j.jacl.2021.12.004_bib0020 article-title: Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy publication-title: Anal Chim Acta doi: 10.1016/j.aca.2011.01.034 – volume: 290 start-page: 25863 year: 2015 ident: 10.1016/j.jacl.2021.12.004_bib0013 article-title: Microsomal triglyceride transfer protein transfers and determines plasma concentrations of ceramide and sphingomyelin but Not glycosylceramide publication-title: J Biol Chem doi: 10.1074/jbc.M115.659110 – volume: 13 start-page: 468 year: 2019 ident: 10.1016/j.jacl.2021.12.004_bib0028 publication-title: .Journal of Clinical Lipidology doi: 10.1016/j.jacl.2019.02.004 – volume: 32 start-page: 20 year: 1983 ident: 10.1016/j.jacl.2021.12.004_bib0025 article-title: Effect of Metabolic Control on lipid, lipoprotein, and apolipoprotein levesl in 55 insulin-dependent diabetic patients. A longitudinal study publication-title: Diabetes doi: 10.2337/diab.32.1.20 – volume: 51 start-page: 3074 year: 2010 ident: 10.1016/j.jacl.2021.12.004_bib0010 article-title: Blood sphingolipidomics in healthy humans: impact of sample collection and methodology publication-title: J Lipid Res doi: 10.1194/jlr.D008532 – volume: 51 start-page: 2619 year: 2010 ident: 10.1016/j.jacl.2021.12.004_bib0024 article-title: HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate publication-title: J Lipid Res doi: 10.1194/jlr.M003988 – volume: 13 issue: 3 year: 2018 ident: 10.1016/j.jacl.2021.12.004_bib0037 article-title: Type 2 diabetes is associated with loss of HDL endothelium protective functions publication-title: PLoS One doi: 10.1371/journal.pone.0192616 – volume: 2 start-page: 470 issue: 3 year: 2016 ident: 10.1016/j.jacl.2021.12.004_bib0022 article-title: Profiling of plasma metabolites suggests altered mitochondrial fuel usage and remodeling of sphingolipid metabolism in individuals with type 2 diabetes and kidney disease publication-title: Kidney Int Rep doi: 10.1016/j.ekir.2016.12.003 – year: 2014 ident: 10.1016/j.jacl.2021.12.004_bib0015 – volume: 63 start-page: 1847 issue: 9 year: 2020 ident: 10.1016/j.jacl.2021.12.004_bib0018 article-title: Groop PH; FinnDiane Study Group. Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes publication-title: Diabetologia doi: 10.1007/s00125-020-05201-9 – volume: 352 start-page: 809 year: 2000 ident: 10.1016/j.jacl.2021.12.004_bib0012 article-title: Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions publication-title: Biochem J doi: 10.1042/bj3520809 – volume: 104 start-page: 333 issue: 3 year: 2009 ident: 10.1016/j.jacl.2021.12.004_bib0034 article-title: The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes publication-title: Basic Res Cardiol doi: 10.1007/s00395-008-0769-1 – volume: 53 start-page: 637 issue: 13 year: 1975 ident: 10.1016/j.jacl.2021.12.004_bib0007 article-title: Plasma glycosphingolipids in diabetics and normals publication-title: Klin Wochenschr doi: 10.1007/BF01469685 – volume: 35 issue: 2 year: 2021 ident: 10.1016/j.jacl.2021.12.004_bib0002 article-title: Role of ceramides in the pathogenesis of diabetes mellitus and its complications publication-title: J Diabetes Complications doi: 10.1016/j.jdiacomp.2020.107734 – volume: 241 start-page: 752 issue: 2 year: 2015 ident: 10.1016/j.jacl.2021.12.004_bib0038 article-title: Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2015.06.040 – year: 2012 ident: 10.1016/j.jacl.2021.12.004_bib0026 article-title: Sphingosine 1-phosphate distribution in plasma: associations with atypical lipoprotein profiles publication-title: J Lipids doi: 10.1155/2012/180705 – volume: 8 start-page: 369 year: 2012 ident: 10.1016/j.jacl.2021.12.004_bib0017 article-title: Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study) publication-title: Metabolomics doi: 10.1007/s11306-011-0343-y – start-page: 373 issue: 216 year: 2013 ident: 10.1016/j.jacl.2021.12.004_bib0006 article-title: Sphingolipids in obesity, type 2 diabetes, and metabolic disease publication-title: Handb Exp Pharmacol doi: 10.1007/978-3-7091-1511-4_19 – volume: 85 start-page: 1711 issue: 4 year: 2011 ident: 10.1016/j.jacl.2021.12.004_bib0021 article-title: Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy publication-title: Talanta doi: 10.1016/j.talanta.2011.05.036 – volume: 12 start-page: 27 year: 2013 ident: 10.1016/j.jacl.2021.12.004_bib0035 article-title: High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate publication-title: Cardiovasc Diabetol doi: 10.1186/1475-2840-12-27 – volume: 13 start-page: 481 year: 2019 ident: 10.1016/j.jacl.2021.12.004_bib0004 article-title: Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes publication-title: J Clin Lipidol doi: 10.1016/j.jacl.2019.03.005 – volume: 155 start-page: 57 year: 2008 ident: 10.1016/j.jacl.2021.12.004_bib0011 article-title: Reconsideration of hydrophobic lipid distributions in lipoprotein particles publication-title: Chem. Phys. Lipids. doi: 10.1016/j.chemphyslip.2008.06.003 – volume: 11 year: 2021 ident: 10.1016/j.jacl.2021.12.004_bib0033 article-title: Rotten to the cortex: ceramide-mediated lipotoxicity in diabetic kidney disease publication-title: Front Endocrinol (Lausanne) doi: 10.3389/fendo.2020.622692 |
SSID | ssj0055705 |
Score | 2.330718 |
Snippet | •Assessing sphingolipid distribution in plasma lipoproteins is clinically valuable.•Plasma levels do not consistently reflect changes in circulating... We have previously shown that very long ceramides/lactosylceramides predicted the development of macroalbuminuria (MA) in type 1 diabetes and expanded our... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 173 |
SubjectTerms | Albuminuria Ceramide Dihydrosphingosine Glycosphingolipid Hexosylceramide Lactosylceramide Macroalbuminuria Sphingolipid Sphingomyelin Sphingosine Type 2 diabetes |
Title | Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1933287421003512 https://dx.doi.org/10.1016/j.jacl.2021.12.004 https://www.ncbi.nlm.nih.gov/pubmed/35148982 https://www.proquest.com/docview/2628298510 |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYQXHqpqKDtQlkZqbcq3bycxEeEQFtQ99IicbPssVMFlmS12T3shd_OTOKshERB4ppkFGs8nvnG82LsOzpcMjSlDIwT6KDkOQTauCiIRYKq0BWQWCpO_j3Lpjfp1a243WHnQy0MpVV63d_r9E5b-ycTz83JoqomfxB6JNStHZ0WCoeRHk7TnKT85-M2zYM6TIk-spwE9LUvnOlzvO40UPghjrorQT-s7QXj9D_w2Rmhy3320aNHftYv8BPbcfUBa3xWS8t1bfl9ZWu34XbTkskitvMHSsGx8w3vQuMcIR-nDHU0N7wpebugS6hmXi0q23LQS3SeLTcbDtUSuuFe9T-Ob5uupUNVt4fs5vLi7_k08HMUAkhFtAqMNSBNWOosdXGUQY5n2iRaRlo6kxmbQAhZXkYWJKKlMo9LKcrMZqUIAWRaJJ_Zbt3U7ivjiD5AICYEnSOUMUYjHHTapEWqTS5EMWLRwEAFvsk4zbqYqyGb7E4R0xUxXUWxQqaP2I8tzaJvsfHq18mwL2ooHkV1p9ACvEoltlTPxOtNutNh6xWeOwqm6No161bFGcWgEa-GI_all4nt6qk6opBFfPTOvx6zDzFVWXSpbt_Y7mq5dieIfVZm3An3mO2d_bqezp4Adv8EjQ |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOXBCIF4LBYwEJxQ2duIkPnBALdWWPi60Um_Gr6C022S12arKpX-qf5CZxFkJCYqE1GuSSaIZe-Ybz4uQ9-BwydiUMjJegIOS5zbSxrOIiwRUoS9s4rA4-fAom52k307F6Qa5GWthMK0y6P5Bp_faOlyZBm5OF1U1_Q7QI8Fu7eC0YDiMh8zKfd9dgd_Wft7bASF_4Hz36_H2LAqjBSKbCraKjDNWmrjUWeo5y2wOy9wkWjItvcmMS2xss7xkzkoAEGXOSynKzGWliK2VaZHAe--R-ymoCxyb8Ol6nVeCLa3EEMpOIvy9UKkzJJWdaYvxDs76M8gwHe4P1vBvaLe3eruPyMMAV-mXgSOPyYavn5AmpNG0VNeOnleu9h11XYs2EuVMLzDnx8072sfiKWBMiinxYN9oU9J2gadezbxaVK6lVi_BW3fUdNRWS9tPE6t_Urjb9D0kqrp9Sk7uhLvPyGbd1P4FoQB3rAAQanUO2MkYDfjTa5MWqTa5EMWEsJGByoau5jhcY67G9LUzhUxXyHTFuAKmT8jHNc1i6Olx69PJKBc1VquCflVgcm6lEmuq39bzP-nejaJXsNExeqNr31y2imcY9AaAHE_I82FNrP8eyzEKWfCX__nVt-TB7PjwQB3sHe2_wqOLfsRkFLMtsrlaXvrXALxW5k2_0Cn5cdc76xfkD0F1 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diabetes+and+kidney+dysfunction+markedly+alter+the+content+of+sphingolipids+carried+by+circulating+lipoproteins&rft.jtitle=Journal+of+clinical+lipidology&rft.au=Hammad%2C+Samar+M&rft.au=Hunt%2C+Kelly+J&rft.au=Baker%2C+Nathaniel+L&rft.au=Klein%2C+Richard+L&rft.date=2022-03-01&rft.issn=1933-2874&rft.volume=16&rft.issue=2&rft.spage=173&rft_id=info:doi/10.1016%2Fj.jacl.2021.12.004&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1933-2874&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1933-2874&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1933-2874&client=summon |